Evidence map›Paper›PMID 42373897›Full record

Trial reportCardiovascular and interventional radiology2026

Predilation-Free Scoring Paclitaxel-Coated Balloon Versus Conventional Plain Balloon Angioplasty for Failing Arteriovenous Access: A Multicenter Randomized Controlled Trial.

Dong-Ping Chen, Ya-Xue Shi, Hua Li, Yang-Dong Liu, Yu-Fei Wang, Zheng-Ya Yu, Hua Jiang, Jian-Guang Ren, Jun Xue, Pei Wang and 1 more

Abstract readMulticenter StudyRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dong-Ping ChenDepartment of Nephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ya-Xue ShiDepartment of Vascular Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hua LiDepartment of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Yang-Dong LiuDepartment of Vascular Surgery, Jinshan Branch of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yu-Fei WangDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zheng-Ya YuDepartment of Vascular Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Hua JiangDepartment of Nephrology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Jian-Guang RenDepartment of Nephrology, Taiyuan Central Hospital, Taiyuan, Shanxi, China.
Jun XueDepartment of Nephrology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Pei WangDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Wpei@zzu.edu.cn.
Chao-Yang YeDepartment of Nephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. sg3435@shutcm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the efficacy and safety of predilation-free angioplasty with a scoring paclitaxel-coated balloon catheter versus conventional plain balloon angioplasty for failing arteriovenous access. MATERIALS AND

methodsThis prospective multicenter randomized controlled trial enrolled adults with malfunctioning mature arteriovenous fistulas or grafts at nine centers in China between August 21, 2019, and January 4, 2021. Participants were randomly assigned in a 1:1 ratio to predilation-free scoring paclitaxel-coated balloon angioplasty or conventional plain balloon angioplasty. The primary endpoint was 6-month target lesion primary patency. Secondary endpoints included device success, procedural success, clinical success, residual stenosis, 12-month target lesion primary patency, and safety.

resultsA total of 219 treated participants were analyzed, including 109 in the scoring paclitaxel-coated balloon group and 110 in the control group. Six-month target lesion primary patency was 78.9% versus 57.3% (center-adjusted absolute difference, 21.2 percentage points; 95% CI 8.1-37.1 percentage points; P = 0.004). Twelve-month target lesion primary patency was 63.5% (66/104) versus 52.4% (55/105) (absolute difference, 11.1 percentage points; 95% CI - 2.2 to 24.4 percentage points; P = 0.1043). Device success, procedural success, clinical success, mortality, adverse events, and serious adverse events did not differ between groups. Acute gain was greater, and residual stenosis was lower with the scoring paclitaxel-coated balloon.

conclusionPredilation-free angioplasty with a scoring paclitaxel-coated balloon improved a 6-month target lesion primary patency without increasing adverse events in patients with failing arteriovenous access. LEVEL OF EVIDENCE: Level 1, randomized controlled trial.

Indexed as

Angioplasty, BalloonArteriovenous Shunt, SurgicalGraft Occlusion, VascularPaclitaxelAgedChinaCoated Materials, BiocompatibleFemaleHumansMaleMiddle AgedProspective StudiesRenal DialysisTreatment OutcomeVascular PatencyCoated Materials, BiocompatiblePaclitaxelArteriovenous fistulaArteriovenous graftDrug-coated balloonHemodialysisPaclitaxelRandomized controlled trial

Identifiers

PMID42373897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.